Vivek Chaturvedi, MD
Retina Specialist · Harvey, ILNPI 1487789574
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.9%), other and ownership interests — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by US Retina LLC at 33.5% of the total. Reporting peaked in 2023 at $16,611 and has fallen 92.9% since, to $1,177 in 2025.
Across 64 payments — averaging $532.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$11K
- AbbVie$10K
- Regeneron$7K
- Apellis Pharmaceuticals, Inc.$2K
- Bausch & Lomb Americas Inc.$2K
- Alcon$421
- plus $981 from 7 others
Across 584 payments — averaging $1400.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$818K
What the payments were for
- Consulting fees$18,01553%
- Speaking & faculty fees$2,0006%
- Travel & lodging$3331%
- Food & beverage$2,3007%
- Ownership interest$4,77214%
- Other$6,65220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $11,424 |
| AbbVie(2 entities) | 15 | $10,156 |
| Regeneron | 3 | $6,731 |
| Apellis Pharmaceuticals, Inc. | 5 | $2,340 |
| Bausch & Lomb Americas Inc. | 3 | $2,021 |
| Alcon | 4 | $421 |
| Regeneron Healthcare Solutions, Inc. | 8 | $347 |
| Genentech USA, Inc. | 10 | $259 |
| Alimera Sciences, Inc. | 2 | $147 |
| Novartis | 2 | $113 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $51 |
| Notal Vision, Inc. | 1 | $41 |
| Eyepoint US, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,073 in reported general payments places this provider in the 85th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 39 | $4,849 |
| Prednisolone Acetate | 65 | $2,719 |
| Ketorolac Tromethamine | 42 | $1,021 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $318 |
| Brimonidine Tartrate | 14 | $236 |
| Dorzolamide Hcl | 13 | $224 |
| ErythromycinErythromycin Base | 11 | $123 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Harvey
- Mathew MaccumberHarvey$219K
- Kourous RezaeiHarvey$126K
- Kirk PackoHarvey$86K
- David OrthHarvey$70K
- Timothy FloodHarvey$57K
- Serge DebustrosHarvey$34K
- Sohail HasanHarvey$30K
- Jack CohenHarvey$24K
- Zac RavageHarvey$12K
- Naryan SabherwalHarvey$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.